2696 Aktienübersicht Shanghai Henlius Biotech, Inc. beschäftigt sich mit der Erforschung und Entwicklung von biologischen Arzneimitteln mit den Schwerpunkten Onkologie, Autoimmunerkrankungen und Augenkrankheiten. Mehr Details
Belohnungen Risikoanalyse Alle Risikoprüfungen anzeigen Community vs My Fair Value Select a narrative for quick price alerts from the community, or create your own.
Shanghai Henlius Biotech, Inc. Wettbewerber Preisentwicklung & Leistung
Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Shanghai Henlius Biotech Historische Aktienkurse Aktueller Aktienkurs HK$40.35 52-Wochen-Hoch HK$40.40 52-Wochen-Tief HK$15.20 Beta 0.79 1 Monat Veränderung 22.09% 3 Monate Veränderung 124.67% 1 Jahr Veränderung 134.59% 3 Jahre Veränderung 163.38% 5 Jahre Veränderung -8.92% Veränderung seit IPO -18.40%
Aktuelle Nachrichten und Updates
Investor sentiment improves as stock rises 19% Apr 22
Shanghai Henlius Biotech, Inc. Announces First Patient Has Been Dosed in Phase 2 Clinical Study of HLX22 Apr 17
Shanghai Henlius Biotech, Inc., Annual General Meeting, May 08, 2025 Apr 15
Shanghai Henlius Biotech, Inc. Announces First Patient Has Been Dosed in A Phase 1B/2 Clinical Trial of HLX43 for Injection Apr 09
Investor sentiment deteriorates as stock falls 22% Apr 07
Shanghai Henlius Biotech, Inc. Announces Phase 3 Clinical Study of Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection HLX04-O Apr 02 Weitere Updates anzeigen
Investor sentiment improves as stock rises 19% Apr 22
Shanghai Henlius Biotech, Inc. Announces First Patient Has Been Dosed in Phase 2 Clinical Study of HLX22 Apr 17
Shanghai Henlius Biotech, Inc., Annual General Meeting, May 08, 2025 Apr 15
Shanghai Henlius Biotech, Inc. Announces First Patient Has Been Dosed in A Phase 1B/2 Clinical Trial of HLX43 for Injection Apr 09
Investor sentiment deteriorates as stock falls 22% Apr 07
Shanghai Henlius Biotech, Inc. Announces Phase 3 Clinical Study of Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection HLX04-O Apr 02 European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (Pertuzumab) Biosimilar Candidate HLX11
Shanghai Henlius Biotech, Inc. Announces First Patient in Japan Has Been Dosed in an International Multi-Center Phase 3 Clinical Study of HLX22 Mar 26
Shanghai Henlius Biotech, Inc. Announces Application for Phase 2 Clinical Trial of Hlx79 Injection Mar 25
Full year 2024 earnings released: EPS: CN¥1.51 (vs CN¥1.01 in FY 2023) Mar 25
Shanghai Henlius Biotech, Inc. Announces Re-Designation of Wenjie Zhang from Executive Director to A Non-Executive Director Mar 24
New minor risk - Share price stability Mar 20
Investor sentiment improves as stock rises 16% Mar 20
Shanghai Henlius Biotech, Inc. to Report Fiscal Year 2024 Results on Mar 24, 2025 Mar 05
Investor sentiment improves as stock rises 32% Feb 26 Shanghai Henlius Biotech, Inc. Announces the First Patient Has Been Dosed in A Phase 2 Clinical Study of HLX43 for Injection
Investor sentiment improves as stock rises 20% Feb 07
Shanghai Henlius Biotech, Inc. Announces Biologics License Application Forpertuzumab Biosimilar Hlx11(Recombinant Anti-Her2 Domain II Humanizedmonoclonal Antibody Injection) Accepted by the United States Food and Drug Administration Feb 03
Investor sentiment deteriorates as stock falls 17% Jan 15
Shanghai Henlius Biotech, Inc. Announces Approval of Application for Phase 1B/2 Clinical Trial of Hlx43 for Injection (Antibody-Drug Conjugate Targetingpd-L1 with Novel Dna Topoisomerase I Inhibitor) in Combination with Hansizhuang (Serplulimab Injection) Jan 10
Shanghai Henlius Biotech, Inc. Announces First Patient in Mainland China Dosed in an International Multi-Center Phase 3 Clinical Study Dec 24
New major risk - Revenue and earnings growth Dec 13 Shanghai Henlius Biotech Announces Application for the Phase 1b/2 Clinical Trial of HLX43 for Injection Approved by the National Medical Products Administration
Shanghai Henlius Biotech, Inc. Announces New Drug Application for New Indication of Hansizhuang (Serplulimab Injection) Dec 03
Shanghai Henlius Biotech, Inc. Announces First Patient Has Been Dosed in an International Multi-Center Phase 3 Clinical Study of HLX22 Nov 22
US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab) Oct 30
Shanghai Henlius Biotech, Inc. Announces First Patient in Japan Dosed in an International Multicentre Phase 3 Clinical Study of Hansizhuang (Serplulimab Injection) in Combination with Bevacizumab Injection and Chemotherapy for the First-Line Treatment of Metastatic Colorectal Cancer (mCRC) Oct 24
Shanghai Henlius Biotech, Inc. and Organon Announces Phase 3 Comparative Clinical Study of Perjeta®? (pertuzumab) Biosimilar Candidate HLX11 Oct 01
First half 2024 earnings released: EPS: CN¥0.71 (vs CN¥0.44 in 1H 2023) Sep 28
Shanghai Henlius Biotech, Inc. Receives Positive Opinion from the Committee Formedicinal Products for Human Use (Chmp)Of the European Medicines Agency (Ema) Sep 20
Shanghai Henlius Biotech, Inc. Announces Application for the Clinical Trial of Pembrolizumab Biosimilar HLX17 (Recombinant Humanised Anti-PD-1 Monoclonal Antibody Injection) Sep 02
First half 2024 earnings released: EPS: CN¥0.71 (vs CN¥0.44 in 1H 2023) Aug 27
Shanghai Henlius Biotech, Inc. Announces Company Secretary Changes Aug 26
Shanghai Henlius Biotech, Inc. to Report First Half, 2024 Results on Aug 26, 2024 Aug 15
Shanghai Henlius Biotech, Inc. Announces the First Patient Dose in A Phase 2 Clinical Trial of HLX53 Aug 08
Shanghai Henlius Biotech, Inc. Announces International Multicentre Phase 3 Clinical Trial for the First-Line Treatment of Metastatic Colorectal Cancer in Japan Jul 03
Shanghai Henlius Biotech, Inc. Announces Chief Financial Officer Changes Jul 01
Shanghai Henlius Biotech, Inc. Announces Completion of Phase 1 Clinical Study of a Biosimilar of Daratumumab HLX15 (Recombinant Anti-CD38 Human Monoclonal Antibody Jun 28
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) agreed to acquire 78.3% stake in Shanghai Henlius Biotech, Inc. (SEHK:2696) from a group of shareholders for CNY 4.3 billion. Jun 26
Investor sentiment improves as stock rises 19% Jun 26
Less than half of directors are independent Jun 25
Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt? May 25 Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications (Maas) for Hlx14
National Medical Products Administration Approves Shanghai Henlius Biotech, Inc.'S the Supplemental Applications of Handayuan (Adalimumab Injection) for the New Indications May 23
Shanghai Henlius Biotech, Inc. Announces Approval of Application for Clinical Trials of HLX78 (lasofoxifene) by the National Medical Products Administration May 15
Shanghai Henlius Biotech, Inc. Announces Application for the Phase 3 Clinical Trial of HLX22 in Combination with Trastuzumab and Chemotherapy as the First-Line Treatment of HER2 Positive Advanced Gastric Cancer Approved by the United States Food and Drug Administration (FDA) May 06
Shanghai Henlius Biotech, Inc. Announces First Subject Dosed in Phase 1 Clinical Study in Healthy Subjects of HLX6018 in Mainland China Apr 24
Shanghai Henlius Biotech, Inc., Annual General Meeting, May 20, 2024 Apr 19
Shanghai Henlius Biotech, Inc. Announces Application for the Clinical Trial of HLX53 (Anti-TIGIT Fc Fusion Protein) in Combination with HANSIZHUANG (Serplulimab Injection) and HANBEITAI (Bevacizumab Injection) for the First-Line Treatment of Local Advanced or Metastatic Hepatocellular Carcinoma was Approved by the National Medical Products Administration Apr 17
Shanghai Henlius Biotech, Inc Announces Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints Apr 10
Shanghai Henlius Biotech, Inc. Announces International Multi-Centre Phase 3 Clinical Study of Biosimilar of Denosumab HLX14 for Treatment of Osteoporosis in Postmenopausal Women at High Risk for Fracture has Met Primary Study Endpoints Apr 05
Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next Mar 25
Full year 2023 earnings: EPS and revenues exceed analyst expectations Mar 22
Shanghai Henlius Biotech, Inc. Announces the First Patient Has Been Dosed in A Phase 1 Clinical Study of Hlx42 for Injection Mar 15 Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of HLX6018 (Recombinant Anti-GARP/TGF-1 Humanised Monoclonal Antibody Injection) Approved by the National Medical Products Administration
Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking Mar 10
Shanghai Henlius Biotech, Inc. Announces Supplemental New Drug Applications of HANDAYUAN (Adalimumab Injection) for the New Indications Have Been Accepted by the National Medical Products Administration Feb 29
Shanghai Henlius Biotech, Inc. Announces Phase 1 Clinical Study of A Biosimilar of Denosumab HLX14 Successfully Completed Feb 01
Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load Dec 31
Shanghai Henlius Biotech, Inc. Receives Fast Track Designation by the United States Food and Drug Administration Dec 27
New major risk - Financial position Dec 24
Shanghai Henlius Biotech, Inc. Announces the New Drug Application (Nda) for New Indication Ofhansizhuang (Serplulimab Injection) in Combination Withchemotherapy for the First-Line Treatment Oflocally Advanced or Metastatic Non-Squamous Non-Smallcell Lung Cancer (NSCLC) Has Been Accepted By the National Medical Products Administration Dec 15
Shanghai Henlius Biotech, Inc. Announces Dosing of First Subject in A Phase 1 Clinical Studyin Healthy Chinese Male Subjects of Ipilimumab Biosimilarhlx13 (Recombinant Anti-Ctla-4 Fully Human Monoclonalantibody Injection) Dec 13
Shanghai Henlius Biotech, Inc. Announces Application for Phase 1 Clinical Trial of Hlx43 for Injection Nov 29
The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business Nov 25
Shanghai Henlius Biotech, Inc. Receives Approval from United States Food and Drug Administration for Application for Phase 1 Clinical Trial of HLX42 for Injection (Antibody-Drug Conjugate Targeting EGFR with Novel DNA Topoisomerase I Inhibitor) Nov 24
Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of Ipilimumab Biosimilar HLX13 Nov 21
New minor risk - Financial position Nov 17
Shanghai Henlius Biotech, Inc. to Report Nine Months, 2023 Results on Nov 15, 2023 Nov 04
Shanghai Henlius Biotech, Inc. Announces Shenzhen Nansiuzhuiang in Combination with Chemotherapy for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Nov 01 Shanghai Henlius Biotech, Inc. Announces NMPA Approvals of Two ADC Candidates for IND
Shanghai Henlius Biotech, Inc. Announces the First Patient in Europe Has Been Dosed in the International Multi-Centre Phase 3 Clinical Trial Oct 26
Shanghai Henlius Biotech, Inc. Appoints Wei Huang as President Oct 05
Shanghai Henlius Biotech, Inc. Announces the New Drug Application (Nda) for New Indication of Hansizhuang (Serplulimab Injection) an Innovative Anti-PD-1 Monoclonal Antibody Sep 23
Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt? Sep 18
Shanghai Henlius Biotech, Inc. Announces Executive Appointments Aug 29
First half 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.47 loss in 1H 2022) Aug 26
Shanghai Henlius Biotech, Inc. to Report Q2, 2023 Results on Aug 25, 2023 Aug 16
Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet Aug 03
Forecast breakeven date moved forward to 2023 Jul 19 Shanghai Henlius Biotech, Inc. Announces Resignation of Zihou Yan as Non-Executive Director, Member of the Strategy Committee and Environmental, Social and Governance Committee
Consensus EPS estimates fall by 31% Jul 06
Shanghai Henlius Biotech, Inc. Provides Unaudited Consolidated Financial Guidance for the Six Months Ended 30 June 2023 Jul 06
Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of Ipilimumab Biosimilar HLX13 (Recombinant Anti-CTLA-4 Fully Human Monoclonal Antibody Injection) Approved by the National Medical Products Administration Jun 27
Shanghai Henlius Biotech, Inc. Announces Dosing of First Patient in a Phase 2 Clinical Trial of HLX26 Jun 16
Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry? May 31
Shanghai Henlius Biotech, Inc. Announces Application for Phase 2 Clinical Trial of Hlx26 May 06
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Apr 26 Aktionärsrenditen 2696 HK Biotechs HK Markt 7D 5.2% 2.9% 1.5% 1Y 134.6% 52.7% 14.7%
Vollständige Aktionärsrenditen anzeigen
Rendite im Vergleich zur Industrie: 2696 übertraf die Branche Hong Kong Biotechs , die im vergangenen Jahr eine Rendite von 52.7 erzielte.
Rendite vs. Markt: 2696 übertraf den Markt Hong Kong, der im vergangenen Jahr eine Rendite von 14.7 erzielte.
Preisvolatilität Is 2696's price volatile compared to industry and market? 2696 volatility 2696 Average Weekly Movement 13.1% Biotechs Industry Average Movement 13.9% Market Average Movement 8.1% 10% most volatile stocks in HK Market 15.3% 10% least volatile stocks in HK Market 4.2%
Stabiler Aktienkurs: Der Aktienkurs von 2696 war in den letzten 3 Monaten im Vergleich zum Hong Kong -Markt volatil.
Volatilität im Zeitverlauf: 2696Die wöchentliche Volatilität (13%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der Hong Kong Aktien.
Über das Unternehmen Shanghai Henlius Biotech, Inc. beschäftigt sich mit der Erforschung und Entwicklung von biologischen Arzneimitteln mit den Schwerpunkten Onkologie, Autoimmunerkrankungen und Augenkrankheiten. Das Unternehmen bietet HANLIKANG, eine Rituximab-Injektion zur Behandlung von aktiver Glomerulonephritis, HANQUYOU, eine Trastuzumab-Injektion zur Behandlung von Brustkrebs und metastasiertem Brust- und Magenkrebs; HANDAYUAN, eine Adalimumab-Injektion zur Behandlung von rheumatoider Arthritis, Spondylitis ankylosans, Psoriasis, Uveitis, polyartikulärer juveniler idiopathischer Arthritis und pädiatrischer Plaque-Psoriasis; und HANBEITAI, eine Bevacizumab-Injektion zur Behandlung von metastasierendem kolorektalem Karzinom (mCRC) und rezidivierendem nicht-kleinzelligem Lungenkrebs. Das Unternehmen entwickelt außerdem: HANSIZHUANG, eine Serplulimab-Injektion zur Behandlung von Dickdarmkrebs, Magenkarzinom und kleinzelligem Lungenkrebs im fortgeschrittenen Stadium.
Mehr anzeigen Shanghai Henlius Biotech, Inc.'s Grundlagenzusammenfassung Wie verhalten sich die Erträge und Einnahmen von Shanghai Henlius Biotech im Vergleich zum Marktanteil des Unternehmens? 2696 grundlegende Statistiken Marktanteil HK$21.93b Gewinn(TTM ) HK$874.48m Umsatz(TTM ) HK$6.10b
25.1x Kurs-Gewinn-Verhältnis
3.6x Kurs-Umsatz-Verhältnis Erträge & Einnahmen Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM) 2696 Gewinn- und Verlustrechnung (TTM ) Einnahmen CN¥5.72b Kosten der Einnahmen CN¥1.54b Bruttogewinn CN¥4.18b Sonstige Ausgaben CN¥3.36b Umsatz CN¥820.47m
Zuletzt gemeldete Gewinne
Dec 31, 2024
Datum des nächsten Gewinnberichts
k.A.
Gewinn per Aktie (EPS) 1.51 Bruttomarge 73.10% Nettogewinnspanne 14.33% Schulden/Eigenkapital-Verhältnis 114.3%
Wie hat sich 2696 auf lange Sicht entwickelt?
Historische Performance und Vergleiche
Unternehmensanalyse und Finanzdaten Status Daten Zuletzt aktualisiert (UTC-Zeit) Unternehmensanalyse 2025/05/06 02:15 Aktienkurs zum Tagesende 2025/05/02 00:00 Gewinne 2024/12/31 Jährliche Einnahmen 2024/12/31
Datenquellen Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC . Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
Paket Daten Zeitrahmen Beispiel US-Quelle * Finanzdaten des Unternehmens 10 Jahre Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz Konsensschätzungen der Analysten +3 Jahre Finanzielle Vorausschau Kursziele der Analysten Marktpreise 30 Jahre Aktienkurse Dividenden, Splits und Aktionen Eigentümerschaft 10 Jahre Top-Aktionäre Insiderhandel Verwaltung 10 Jahre Das Führungsteam Direktorium Wichtige Entwicklungen 10 Jahre Ankündigungen des Unternehmens
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr .
Analysemodell und Schneeflocke Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite . Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube .
Erfahren Sie mehr über das Weltklasse-Team , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github .
Analysten-Quellen Shanghai Henlius Biotech, Inc. wird von 14 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
Analyst Einrichtung Yang Huang BofA Global Research Wangbin Zhou Citigroup Inc Wai Ming Kong DBS Bank Ltd
11 weitere Analysten anzeigen 
